Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug-Eluting Stents | 82 | 2024 | 679 | 8.690 |
Why?
|
Angioplasty, Balloon, Coronary | 89 | 2024 | 1730 | 7.570 |
Why?
|
Stents | 110 | 2024 | 3162 | 6.680 |
Why?
|
Coronary Restenosis | 54 | 2024 | 396 | 4.690 |
Why?
|
Coronary Thrombosis | 34 | 2024 | 440 | 4.000 |
Why?
|
Sirolimus | 53 | 2022 | 1533 | 3.990 |
Why?
|
Coronary Artery Disease | 69 | 2024 | 6362 | 3.330 |
Why?
|
Coronary Stenosis | 28 | 2020 | 793 | 2.940 |
Why?
|
Myocardial Infarction | 98 | 2022 | 11424 | 2.800 |
Why?
|
Cardiovascular Agents | 24 | 2024 | 839 | 2.280 |
Why?
|
Platelet Aggregation Inhibitors | 47 | 2024 | 2747 | 2.230 |
Why?
|
Paclitaxel | 28 | 2016 | 1728 | 2.080 |
Why?
|
Endpoint Determination | 22 | 2019 | 590 | 1.920 |
Why?
|
Creatine Kinase, MB Form | 14 | 2019 | 202 | 1.620 |
Why?
|
Renal Artery Obstruction | 10 | 2019 | 219 | 1.500 |
Why?
|
Prosthesis Design | 41 | 2024 | 2105 | 1.500 |
Why?
|
Coated Materials, Biocompatible | 7 | 2024 | 312 | 1.380 |
Why?
|
Coronary Angiography | 64 | 2023 | 4451 | 1.330 |
Why?
|
Myocardial Revascularization | 11 | 2020 | 792 | 1.330 |
Why?
|
Hemorrhage | 30 | 2024 | 3400 | 1.310 |
Why?
|
Acute Coronary Syndrome | 10 | 2023 | 2180 | 1.200 |
Why?
|
Clinical Trials as Topic | 34 | 2022 | 7985 | 1.150 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 17 | 2015 | 577 | 1.090 |
Why?
|
Heart Valve Prosthesis Implantation | 16 | 2023 | 1547 | 1.090 |
Why?
|
Aspirin | 21 | 2021 | 3131 | 1.030 |
Why?
|
Polymers | 7 | 2022 | 1616 | 1.030 |
Why?
|
Treatment Outcome | 157 | 2024 | 64378 | 1.010 |
Why?
|
Intermittent Claudication | 7 | 2015 | 303 | 0.940 |
Why?
|
Thrombosis | 22 | 2022 | 2929 | 0.920 |
Why?
|
Immunosuppressive Agents | 22 | 2018 | 4158 | 0.900 |
Why?
|
Coronary Disease | 29 | 2019 | 5917 | 0.900 |
Why?
|
Endarterectomy, Carotid | 10 | 2018 | 549 | 0.890 |
Why?
|
Troponin | 5 | 2012 | 500 | 0.780 |
Why?
|
Absorbable Implants | 8 | 2022 | 338 | 0.770 |
Why?
|
Product Surveillance, Postmarketing | 2 | 2017 | 451 | 0.750 |
Why?
|
Equipment and Supplies | 3 | 2018 | 273 | 0.710 |
Why?
|
Time Factors | 77 | 2024 | 39872 | 0.710 |
Why?
|
Metals | 6 | 2019 | 717 | 0.700 |
Why?
|
Risk Assessment | 52 | 2024 | 23884 | 0.690 |
Why?
|
Coronary Vessels | 9 | 2021 | 3072 | 0.690 |
Why?
|
Terminology as Topic | 9 | 2019 | 1533 | 0.670 |
Why?
|
Carotid Stenosis | 8 | 2018 | 853 | 0.660 |
Why?
|
Iliac Artery | 3 | 2015 | 342 | 0.650 |
Why?
|
Humans | 288 | 2024 | 758406 | 0.610 |
Why?
|
Follow-Up Studies | 69 | 2024 | 39059 | 0.580 |
Why?
|
Device Approval | 2 | 2016 | 164 | 0.560 |
Why?
|
Middle Aged | 161 | 2024 | 219568 | 0.550 |
Why?
|
Aged | 137 | 2024 | 168218 | 0.550 |
Why?
|
Pyridines | 11 | 2019 | 2859 | 0.550 |
Why?
|
Cardiology | 4 | 2018 | 1667 | 0.550 |
Why?
|
Angioplasty | 9 | 2015 | 354 | 0.540 |
Why?
|
Ticlopidine | 9 | 2017 | 731 | 0.540 |
Why?
|
Risk Factors | 76 | 2024 | 73809 | 0.530 |
Why?
|
Kaplan-Meier Estimate | 28 | 2017 | 6493 | 0.530 |
Why?
|
Blood Vessel Prosthesis Implantation | 12 | 2018 | 1426 | 0.520 |
Why?
|
Graft Occlusion, Vascular | 9 | 2011 | 537 | 0.500 |
Why?
|
Constriction, Pathologic | 6 | 2015 | 1097 | 0.490 |
Why?
|
Diabetes Complications | 5 | 2012 | 1317 | 0.490 |
Why?
|
Death | 5 | 2022 | 674 | 0.490 |
Why?
|
Financial Management | 1 | 2016 | 160 | 0.480 |
Why?
|
Male | 173 | 2024 | 358747 | 0.480 |
Why?
|
Prospective Studies | 58 | 2024 | 54137 | 0.480 |
Why?
|
Embolism | 9 | 2013 | 401 | 0.470 |
Why?
|
Postoperative Complications | 22 | 2018 | 15637 | 0.470 |
Why?
|
Fibromuscular Dysplasia | 1 | 2014 | 54 | 0.470 |
Why?
|
Female | 174 | 2024 | 390323 | 0.460 |
Why?
|
Heart Atria | 7 | 2024 | 1344 | 0.460 |
Why?
|
Stroke | 18 | 2024 | 9694 | 0.450 |
Why?
|
Registries | 19 | 2020 | 8175 | 0.430 |
Why?
|
Stroke Volume | 10 | 2024 | 5460 | 0.430 |
Why?
|
Drug Therapy, Combination | 20 | 2024 | 6293 | 0.430 |
Why?
|
Renal Insufficiency, Chronic | 7 | 2023 | 2239 | 0.430 |
Why?
|
Accreditation | 1 | 2016 | 473 | 0.430 |
Why?
|
Cerebral Revascularization | 2 | 2012 | 250 | 0.420 |
Why?
|
Aortic Valve | 9 | 2024 | 1950 | 0.420 |
Why?
|
Diabetic Angiopathies | 3 | 2013 | 802 | 0.420 |
Why?
|
Donor Selection | 1 | 2014 | 227 | 0.410 |
Why?
|
Patient Selection | 13 | 2017 | 4244 | 0.410 |
Why?
|
Academies and Institutes | 2 | 2012 | 319 | 0.410 |
Why?
|
Unnecessary Procedures | 1 | 2015 | 411 | 0.400 |
Why?
|
Myocardial Ischemia | 8 | 2015 | 2108 | 0.400 |
Why?
|
Consensus | 10 | 2024 | 3099 | 0.400 |
Why?
|
Angina Pectoris, Variant | 1 | 2011 | 53 | 0.400 |
Why?
|
Proportional Hazards Models | 23 | 2017 | 12440 | 0.400 |
Why?
|
Coronary Circulation | 8 | 2015 | 1561 | 0.380 |
Why?
|
Diabetes Mellitus | 8 | 2019 | 5816 | 0.370 |
Why?
|
Heart Failure | 11 | 2024 | 11593 | 0.370 |
Why?
|
United States Food and Drug Administration | 4 | 2018 | 1659 | 0.360 |
Why?
|
Randomized Controlled Trials as Topic | 26 | 2020 | 10146 | 0.360 |
Why?
|
Creatine Kinase | 6 | 2013 | 686 | 0.350 |
Why?
|
Cardiovascular Diseases | 13 | 2018 | 15399 | 0.350 |
Why?
|
Single-Blind Method | 18 | 2018 | 1570 | 0.350 |
Why?
|
Biomedical Research | 3 | 2017 | 3418 | 0.350 |
Why?
|
Fractional Flow Reserve, Myocardial | 2 | 2012 | 317 | 0.350 |
Why?
|
Drug Delivery Systems | 9 | 2013 | 2212 | 0.350 |
Why?
|
Hemodynamics | 1 | 2020 | 4159 | 0.350 |
Why?
|
Aorta | 2 | 2015 | 2037 | 0.350 |
Why?
|
Heart-Assist Devices | 2 | 2023 | 1279 | 0.340 |
Why?
|
Peripheral Arterial Disease | 7 | 2017 | 1246 | 0.330 |
Why?
|
Hypothermia, Induced | 2 | 2011 | 756 | 0.330 |
Why?
|
Decision Support Techniques | 3 | 2016 | 1996 | 0.330 |
Why?
|
Peer Review, Research | 1 | 2012 | 340 | 0.320 |
Why?
|
Coronary Artery Bypass | 11 | 2020 | 2189 | 0.320 |
Why?
|
Kidney Failure, Chronic | 5 | 2016 | 2457 | 0.320 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2023 | 3227 | 0.320 |
Why?
|
Aortic Valve Stenosis | 9 | 2024 | 2002 | 0.310 |
Why?
|
Atherosclerosis | 7 | 2023 | 3401 | 0.300 |
Why?
|
Survival Rate | 16 | 2019 | 12721 | 0.290 |
Why?
|
Heart Valve Prosthesis | 6 | 2018 | 1466 | 0.290 |
Why?
|
Troponin T | 4 | 2019 | 761 | 0.280 |
Why?
|
Flavins | 2 | 2023 | 18 | 0.280 |
Why?
|
Angioplasty, Balloon | 7 | 2013 | 588 | 0.280 |
Why?
|
Research Design | 13 | 2023 | 6157 | 0.280 |
Why?
|
Predictive Value of Tests | 18 | 2019 | 15225 | 0.270 |
Why?
|
Europe | 13 | 2023 | 3420 | 0.270 |
Why?
|
Incidence | 22 | 2017 | 21272 | 0.270 |
Why?
|
Tissue and Organ Procurement | 1 | 2014 | 943 | 0.260 |
Why?
|
Prostheses and Implants | 1 | 2013 | 1270 | 0.260 |
Why?
|
Ventricular Fibrillation | 1 | 2008 | 537 | 0.260 |
Why?
|
United States | 45 | 2023 | 72136 | 0.260 |
Why?
|
Heart Arrest | 2 | 2016 | 1494 | 0.260 |
Why?
|
Drug Administration Schedule | 7 | 2024 | 4839 | 0.250 |
Why?
|
Atherectomy, Coronary | 6 | 2003 | 142 | 0.250 |
Why?
|
Severity of Illness Index | 20 | 2020 | 15785 | 0.250 |
Why?
|
Nanoparticles | 1 | 2017 | 1940 | 0.250 |
Why?
|
Electrocardiography | 14 | 2018 | 6363 | 0.250 |
Why?
|
Glomerular Filtration Rate | 6 | 2023 | 2154 | 0.240 |
Why?
|
Luciferases | 2 | 2023 | 714 | 0.240 |
Why?
|
Medication Adherence | 2 | 2019 | 2155 | 0.230 |
Why?
|
Logistic Models | 16 | 2015 | 13276 | 0.230 |
Why?
|
Double-Blind Method | 21 | 2018 | 12262 | 0.230 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 2359 | 0.230 |
Why?
|
Tubulin Modulators | 3 | 2013 | 106 | 0.220 |
Why?
|
Heart Diseases | 1 | 2016 | 2782 | 0.210 |
Why?
|
Accidents, Traffic | 1 | 2008 | 814 | 0.210 |
Why?
|
Multivariate Analysis | 14 | 2019 | 12096 | 0.210 |
Why?
|
Practice Guidelines as Topic | 6 | 2016 | 7378 | 0.200 |
Why?
|
Blood Vessel Prosthesis | 4 | 2018 | 953 | 0.200 |
Why?
|
Clinical Competence | 3 | 2016 | 4775 | 0.200 |
Why?
|
New Zealand | 6 | 2015 | 352 | 0.200 |
Why?
|
Exercise Therapy | 3 | 2015 | 919 | 0.200 |
Why?
|
Saphenous Vein | 5 | 2008 | 517 | 0.190 |
Why?
|
Equipment Design | 14 | 2024 | 3507 | 0.190 |
Why?
|
Vasodilator Agents | 2 | 2016 | 973 | 0.190 |
Why?
|
Diagnostic Imaging | 2 | 2015 | 3526 | 0.190 |
Why?
|
Myocardial Reperfusion | 3 | 2010 | 337 | 0.190 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 2 | 2014 | 431 | 0.190 |
Why?
|
Out-of-Hospital Cardiac Arrest | 2 | 2017 | 327 | 0.180 |
Why?
|
Tyrosine | 2 | 2012 | 1432 | 0.180 |
Why?
|
Calgranulin A | 1 | 2021 | 80 | 0.180 |
Why?
|
Venous Thromboembolism | 1 | 2014 | 1855 | 0.180 |
Why?
|
Calgranulin B | 1 | 2021 | 86 | 0.180 |
Why?
|
Isoenzymes | 2 | 2004 | 1686 | 0.180 |
Why?
|
Renal Artery | 3 | 2023 | 351 | 0.180 |
Why?
|
Hypertension | 8 | 2023 | 8499 | 0.170 |
Why?
|
Inpatients | 2 | 2010 | 2551 | 0.170 |
Why?
|
Exercise Test | 3 | 2013 | 2121 | 0.170 |
Why?
|
Odds Ratio | 9 | 2015 | 9650 | 0.170 |
Why?
|
Survival Analysis | 13 | 2018 | 10112 | 0.170 |
Why?
|
Asia | 4 | 2023 | 616 | 0.170 |
Why?
|
Sex Factors | 9 | 2018 | 10504 | 0.160 |
Why?
|
Postoperative Care | 2 | 2017 | 1471 | 0.160 |
Why?
|
Thienopyridines | 1 | 2018 | 9 | 0.160 |
Why?
|
Data Collection | 4 | 2018 | 3322 | 0.160 |
Why?
|
P-Selectin | 1 | 2021 | 597 | 0.160 |
Why?
|
Prosthesis Implantation | 2 | 2023 | 590 | 0.150 |
Why?
|
Cause of Death | 5 | 2019 | 3675 | 0.150 |
Why?
|
Retreatment | 5 | 2013 | 596 | 0.150 |
Why?
|
Coronary Occlusion | 1 | 2021 | 303 | 0.150 |
Why?
|
Australia | 6 | 2013 | 1276 | 0.150 |
Why?
|
Prosthesis Failure | 7 | 2014 | 1198 | 0.140 |
Why?
|
Endovascular Procedures | 4 | 2019 | 2139 | 0.140 |
Why?
|
Cardiovascular Surgical Procedures | 1 | 2018 | 190 | 0.140 |
Why?
|
Alloys | 2 | 2014 | 110 | 0.140 |
Why?
|
Anticoagulants | 4 | 2024 | 4777 | 0.140 |
Why?
|
Vascular Diseases | 3 | 2022 | 1160 | 0.140 |
Why?
|
Fibrinolytic Agents | 3 | 2021 | 2071 | 0.130 |
Why?
|
Atrial Fibrillation | 3 | 2024 | 5103 | 0.130 |
Why?
|
Equipment Safety | 4 | 2011 | 250 | 0.130 |
Why?
|
Internship and Residency | 1 | 2016 | 5865 | 0.130 |
Why?
|
Cost-Benefit Analysis | 10 | 2016 | 5484 | 0.130 |
Why?
|
Organophosphorus Compounds | 1 | 2017 | 203 | 0.130 |
Why?
|
Albuminuria | 2 | 2016 | 650 | 0.130 |
Why?
|
Chi-Square Distribution | 4 | 2013 | 3425 | 0.130 |
Why?
|
Bayes Theorem | 4 | 2017 | 2322 | 0.130 |
Why?
|
Mitral Valve Insufficiency | 2 | 2015 | 1401 | 0.130 |
Why?
|
Antineoplastic Agents, Phytogenic | 4 | 2016 | 623 | 0.130 |
Why?
|
Myocardium | 2 | 2012 | 4690 | 0.130 |
Why?
|
Brain Ischemia | 2 | 2021 | 3047 | 0.130 |
Why?
|
Confidence Intervals | 5 | 2016 | 2925 | 0.130 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 4 | 2016 | 1503 | 0.130 |
Why?
|
Thrombectomy | 3 | 2008 | 690 | 0.120 |
Why?
|
Multicenter Studies as Topic | 6 | 2013 | 1705 | 0.120 |
Why?
|
Hypertension, Renal | 1 | 2015 | 135 | 0.120 |
Why?
|
Retrospective Studies | 15 | 2020 | 80168 | 0.120 |
Why?
|
Internationality | 2 | 2017 | 1000 | 0.120 |
Why?
|
Treatment Failure | 5 | 2013 | 2640 | 0.120 |
Why?
|
Popliteal Artery | 2 | 2014 | 309 | 0.120 |
Why?
|
Preoperative Care | 1 | 2003 | 2249 | 0.120 |
Why?
|
Medical Audit | 1 | 2015 | 452 | 0.120 |
Why?
|
Congresses as Topic | 1 | 2019 | 799 | 0.120 |
Why?
|
Recurrence | 11 | 2019 | 8426 | 0.110 |
Why?
|
Aged, 80 and over | 19 | 2019 | 58683 | 0.110 |
Why?
|
Quality of Life | 14 | 2023 | 13285 | 0.110 |
Why?
|
Bioprosthesis | 1 | 2018 | 591 | 0.110 |
Why?
|
Nitrates | 1 | 2015 | 263 | 0.110 |
Why?
|
Sensitivity and Specificity | 7 | 2013 | 14641 | 0.110 |
Why?
|
Carotid Arteries | 2 | 2015 | 939 | 0.110 |
Why?
|
Shock | 1 | 2016 | 314 | 0.110 |
Why?
|
Ultrasonography, Doppler, Duplex | 1 | 2014 | 198 | 0.110 |
Why?
|
Femoral Artery | 3 | 2014 | 824 | 0.110 |
Why?
|
Smoking | 6 | 2017 | 9051 | 0.110 |
Why?
|
Chromium Alloys | 2 | 2016 | 71 | 0.110 |
Why?
|
Thiophenes | 2 | 2014 | 569 | 0.110 |
Why?
|
Asymptomatic Diseases | 1 | 2016 | 584 | 0.110 |
Why?
|
Massachusetts | 7 | 2016 | 8823 | 0.100 |
Why?
|
Combined Modality Therapy | 7 | 2019 | 8530 | 0.100 |
Why?
|
Vasoconstrictor Agents | 1 | 2016 | 651 | 0.100 |
Why?
|
Reproducibility of Results | 9 | 2021 | 20055 | 0.100 |
Why?
|
Coronary Vessel Anomalies | 1 | 2015 | 308 | 0.100 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2012 | 168 | 0.100 |
Why?
|
Reference Standards | 2 | 2012 | 1003 | 0.100 |
Why?
|
Diagnostic Self Evaluation | 1 | 2013 | 225 | 0.100 |
Why?
|
Comorbidity | 9 | 2018 | 10495 | 0.100 |
Why?
|
Vascular Patency | 3 | 2024 | 895 | 0.090 |
Why?
|
Kidney | 4 | 2023 | 7016 | 0.090 |
Why?
|
Safety | 3 | 2019 | 1147 | 0.090 |
Why?
|
Israel | 3 | 2008 | 721 | 0.090 |
Why?
|
Cardiology Service, Hospital | 1 | 2013 | 239 | 0.090 |
Why?
|
Peptides | 2 | 2012 | 4341 | 0.090 |
Why?
|
Prognosis | 9 | 2023 | 29557 | 0.090 |
Why?
|
Nervous System Diseases | 2 | 2018 | 1647 | 0.090 |
Why?
|
Reimbursement Mechanisms | 1 | 2016 | 663 | 0.090 |
Why?
|
Autopsy | 2 | 2011 | 1003 | 0.090 |
Why?
|
Coronary Care Units | 1 | 2011 | 235 | 0.090 |
Why?
|
Interinstitutional Relations | 1 | 2011 | 236 | 0.090 |
Why?
|
Health Care Costs | 3 | 2014 | 3245 | 0.090 |
Why?
|
Filtration | 2 | 2008 | 227 | 0.080 |
Why?
|
Feasibility Studies | 4 | 2015 | 5199 | 0.080 |
Why?
|
Renin-Angiotensin System | 1 | 2014 | 733 | 0.080 |
Why?
|
Credentialing | 1 | 2010 | 115 | 0.080 |
Why?
|
Health Services | 1 | 2014 | 752 | 0.080 |
Why?
|
Sex Distribution | 1 | 2014 | 2284 | 0.080 |
Why?
|
Organizational Objectives | 1 | 2011 | 427 | 0.080 |
Why?
|
Disease-Free Survival | 7 | 2012 | 6821 | 0.080 |
Why?
|
Echocardiography | 5 | 2024 | 4962 | 0.080 |
Why?
|
Angiography | 1 | 2014 | 1599 | 0.080 |
Why?
|
Myocardial Perfusion Imaging | 4 | 2016 | 570 | 0.080 |
Why?
|
Regional Blood Flow | 1 | 2012 | 1486 | 0.080 |
Why?
|
False Positive Reactions | 1 | 2011 | 956 | 0.080 |
Why?
|
Aortic Diseases | 1 | 2014 | 735 | 0.080 |
Why?
|
Regression Analysis | 5 | 2012 | 6354 | 0.080 |
Why?
|
Age Distribution | 1 | 2014 | 2882 | 0.080 |
Why?
|
Societies, Medical | 5 | 2018 | 3891 | 0.080 |
Why?
|
Age Factors | 8 | 2016 | 18358 | 0.080 |
Why?
|
Antihypertensive Agents | 2 | 2015 | 2016 | 0.080 |
Why?
|
Urokinase-Type Plasminogen Activator | 2 | 2001 | 325 | 0.080 |
Why?
|
Ultrasonography, Interventional | 6 | 2014 | 1489 | 0.080 |
Why?
|
Platelet Activation | 1 | 2011 | 645 | 0.080 |
Why?
|
Hydrocortisone | 1 | 2016 | 1802 | 0.080 |
Why?
|
Disease Management | 3 | 2015 | 2500 | 0.080 |
Why?
|
Cooperative Behavior | 2 | 2014 | 1501 | 0.070 |
Why?
|
Hospitals, Teaching | 1 | 2012 | 1159 | 0.070 |
Why?
|
Boston | 3 | 2017 | 9304 | 0.070 |
Why?
|
Imaging, Three-Dimensional | 1 | 2020 | 4048 | 0.070 |
Why?
|
Atherectomy | 2 | 2015 | 40 | 0.070 |
Why?
|
Education | 1 | 2010 | 533 | 0.070 |
Why?
|
Lower Extremity | 1 | 2015 | 1188 | 0.070 |
Why?
|
Shock, Cardiogenic | 2 | 2023 | 707 | 0.070 |
Why?
|
Mitral Valve | 1 | 2015 | 1466 | 0.070 |
Why?
|
Phosphorylcholine | 1 | 2007 | 153 | 0.070 |
Why?
|
Catheterization, Peripheral | 1 | 2010 | 340 | 0.070 |
Why?
|
Piperazines | 2 | 2014 | 2511 | 0.070 |
Why?
|
Cardiovascular Abnormalities | 1 | 2007 | 143 | 0.070 |
Why?
|
Acute Disease | 5 | 2008 | 7225 | 0.070 |
Why?
|
District of Columbia | 2 | 2019 | 160 | 0.070 |
Why?
|
Diagnostic Tests, Routine | 1 | 2012 | 787 | 0.070 |
Why?
|
Carotid Artery Diseases | 1 | 2012 | 872 | 0.070 |
Why?
|
Obesity | 2 | 2023 | 12870 | 0.070 |
Why?
|
Models, Cardiovascular | 1 | 2011 | 972 | 0.070 |
Why?
|
Hospitalization | 7 | 2018 | 10652 | 0.070 |
Why?
|
World Health Organization | 1 | 2012 | 1312 | 0.060 |
Why?
|
Advisory Committees | 2 | 2014 | 785 | 0.060 |
Why?
|
Radiology, Interventional | 1 | 2010 | 475 | 0.060 |
Why?
|
Guideline Adherence | 1 | 2016 | 2215 | 0.060 |
Why?
|
Walking | 4 | 2015 | 1188 | 0.060 |
Why?
|
Reperfusion Injury | 1 | 2012 | 1022 | 0.060 |
Why?
|
Peripheral Vascular Diseases | 1 | 2008 | 488 | 0.060 |
Why?
|
Drug Implants | 1 | 2005 | 230 | 0.060 |
Why?
|
Adult | 18 | 2022 | 219935 | 0.060 |
Why?
|
Quality Improvement | 2 | 2020 | 3806 | 0.060 |
Why?
|
Kidney Function Tests | 1 | 2007 | 677 | 0.060 |
Why?
|
Intention to Treat Analysis | 2 | 2017 | 414 | 0.060 |
Why?
|
Tissue Donors | 1 | 2014 | 2311 | 0.060 |
Why?
|
Renal Insufficiency | 1 | 2010 | 809 | 0.060 |
Why?
|
Disease Progression | 3 | 2019 | 13468 | 0.060 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2009 | 739 | 0.060 |
Why?
|
Prevalence | 4 | 2014 | 15651 | 0.060 |
Why?
|
Emergency Treatment | 2 | 2008 | 496 | 0.060 |
Why?
|
Statistics as Topic | 2 | 2013 | 2359 | 0.050 |
Why?
|
Erythrocytes | 1 | 2013 | 2413 | 0.050 |
Why?
|
Cardiopulmonary Resuscitation | 3 | 2017 | 985 | 0.050 |
Why?
|
Endosonography | 1 | 2007 | 607 | 0.050 |
Why?
|
Time | 2 | 2002 | 543 | 0.050 |
Why?
|
Sampling Studies | 1 | 2004 | 614 | 0.050 |
Why?
|
Kidney Diseases | 2 | 2011 | 2083 | 0.050 |
Why?
|
Vascular Surgical Procedures | 2 | 2010 | 1470 | 0.050 |
Why?
|
Cohort Studies | 12 | 2015 | 41256 | 0.050 |
Why?
|
Ventricular Remodeling | 2 | 2023 | 1256 | 0.050 |
Why?
|
Dinucleoside Phosphates | 1 | 2022 | 72 | 0.050 |
Why?
|
Anemia, Pernicious | 1 | 1981 | 15 | 0.050 |
Why?
|
Immunoglobulin Fab Fragments | 2 | 2015 | 444 | 0.050 |
Why?
|
Hospital Mortality | 4 | 2012 | 5272 | 0.050 |
Why?
|
Heart Valve Diseases | 1 | 2009 | 1033 | 0.050 |
Why?
|
Ischemia | 2 | 2022 | 1863 | 0.040 |
Why?
|
Ventricular Function, Left | 2 | 2023 | 3858 | 0.040 |
Why?
|
American Heart Association | 2 | 2015 | 1039 | 0.040 |
Why?
|
Linear Models | 4 | 2016 | 5862 | 0.040 |
Why?
|
Mass Screening | 1 | 2016 | 5427 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2010 | 2850 | 0.040 |
Why?
|
Heart | 2 | 2023 | 4382 | 0.040 |
Why?
|
Hemostasis, Surgical | 1 | 2000 | 127 | 0.040 |
Why?
|
Paris | 1 | 2019 | 42 | 0.040 |
Why?
|
Hyperlipidemias | 1 | 2004 | 772 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 3 | 2014 | 1722 | 0.040 |
Why?
|
Blood Pressure | 4 | 2016 | 8451 | 0.040 |
Why?
|
CD40 Ligand | 1 | 2021 | 519 | 0.040 |
Why?
|
Pulmonary Circulation | 1 | 2022 | 743 | 0.040 |
Why?
|
Platelet Function Tests | 1 | 2021 | 271 | 0.040 |
Why?
|
Kidney Transplantation | 1 | 2014 | 4217 | 0.040 |
Why?
|
New York | 1 | 2001 | 874 | 0.040 |
Why?
|
Brachytherapy | 1 | 2007 | 1236 | 0.040 |
Why?
|
Hypotension, Orthostatic | 1 | 1981 | 256 | 0.040 |
Why?
|
Anti-Inflammatory Agents | 1 | 2008 | 1793 | 0.040 |
Why?
|
Models, Economic | 2 | 2014 | 715 | 0.040 |
Why?
|
Lipids | 1 | 2009 | 3326 | 0.040 |
Why?
|
Thromboembolism | 1 | 2024 | 996 | 0.040 |
Why?
|
Contrast Media | 1 | 2011 | 5298 | 0.040 |
Why?
|
Postoperative Hemorrhage | 1 | 2021 | 413 | 0.040 |
Why?
|
Medicare | 1 | 2016 | 6741 | 0.040 |
Why?
|
Recovery of Function | 3 | 2015 | 2970 | 0.040 |
Why?
|
Blood Platelets | 1 | 2008 | 2475 | 0.040 |
Why?
|
Catheters, Indwelling | 1 | 2000 | 428 | 0.040 |
Why?
|
Exercise | 2 | 2015 | 5788 | 0.040 |
Why?
|
Reoperation | 2 | 2004 | 4282 | 0.040 |
Why?
|
Hypertension, Portal | 1 | 2019 | 226 | 0.040 |
Why?
|
Netherlands | 2 | 2012 | 2212 | 0.030 |
Why?
|
Adenosine | 1 | 2021 | 802 | 0.030 |
Why?
|
Administration, Oral | 1 | 2024 | 3991 | 0.030 |
Why?
|
Plasminogen Activators | 1 | 1996 | 199 | 0.030 |
Why?
|
Health Services Accessibility | 2 | 2011 | 5404 | 0.030 |
Why?
|
Angina Pectoris | 2 | 2011 | 958 | 0.030 |
Why?
|
Sutures | 1 | 2018 | 293 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 2269 | 0.030 |
Why?
|
Canada | 2 | 2015 | 2111 | 0.030 |
Why?
|
Radiography | 3 | 2015 | 6954 | 0.030 |
Why?
|
South Africa | 2 | 2015 | 1821 | 0.030 |
Why?
|
Echocardiography, Stress | 1 | 2016 | 134 | 0.030 |
Why?
|
Control Groups | 1 | 2015 | 104 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2019 | 610 | 0.030 |
Why?
|
Health Insurance Portability and Accountability Act | 1 | 2015 | 105 | 0.030 |
Why?
|
Egypt | 1 | 2015 | 98 | 0.030 |
Why?
|
Suture Techniques | 1 | 2000 | 788 | 0.030 |
Why?
|
Western Australia | 1 | 2014 | 41 | 0.030 |
Why?
|
South America | 1 | 2015 | 180 | 0.030 |
Why?
|
Neurologic Examination | 1 | 2018 | 914 | 0.030 |
Why?
|
ROC Curve | 1 | 2002 | 3563 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2021 | 960 | 0.030 |
Why?
|
Causality | 1 | 2001 | 1241 | 0.030 |
Why?
|
Hypoglycemic Agents | 1 | 2007 | 3069 | 0.030 |
Why?
|
Risk | 3 | 2015 | 9599 | 0.030 |
Why?
|
Endarterectomy | 1 | 2015 | 195 | 0.030 |
Why?
|
Medicine | 2 | 2015 | 942 | 0.030 |
Why?
|
Health Status Indicators | 2 | 2015 | 970 | 0.030 |
Why?
|
Echocardiography, Doppler, Color | 1 | 2015 | 352 | 0.030 |
Why?
|
Aortic Valve Insufficiency | 1 | 2018 | 578 | 0.030 |
Why?
|
Amlodipine | 1 | 2013 | 84 | 0.030 |
Why?
|
Workflow | 1 | 2018 | 850 | 0.030 |
Why?
|
Mortality | 2 | 2017 | 2886 | 0.030 |
Why?
|
Italy | 1 | 2015 | 839 | 0.030 |
Why?
|
Catheterization | 1 | 2018 | 1426 | 0.030 |
Why?
|
Neointima | 1 | 2013 | 133 | 0.030 |
Why?
|
Insulin | 1 | 2007 | 6578 | 0.030 |
Why?
|
Quality Assurance, Health Care | 2 | 2015 | 2167 | 0.030 |
Why?
|
Erythrocyte Count | 1 | 2013 | 157 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2002 | 2638 | 0.030 |
Why?
|
History, 20th Century | 1 | 2000 | 2772 | 0.030 |
Why?
|
Fibrosis | 1 | 2019 | 2038 | 0.030 |
Why?
|
Heptanoic Acids | 1 | 2013 | 344 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2003 | 3561 | 0.020 |
Why?
|
Tissue Scaffolds | 1 | 2018 | 926 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2019 | 1171 | 0.020 |
Why?
|
Confidentiality | 1 | 2015 | 610 | 0.020 |
Why?
|
Catheter Ablation | 1 | 2004 | 2740 | 0.020 |
Why?
|
Arterial Occlusive Diseases | 1 | 2015 | 747 | 0.020 |
Why?
|
San Francisco | 1 | 2011 | 162 | 0.020 |
Why?
|
Heart Injuries | 1 | 2012 | 205 | 0.020 |
Why?
|
Up-Regulation | 1 | 2019 | 4113 | 0.020 |
Why?
|
Software Validation | 1 | 2010 | 59 | 0.020 |
Why?
|
Young Adult | 2 | 2014 | 58808 | 0.020 |
Why?
|
Warfarin | 1 | 1998 | 1482 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2013 | 10748 | 0.020 |
Why?
|
Anemia | 1 | 2019 | 1504 | 0.020 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2016 | 1016 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2016 | 1808 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2016 | 1474 | 0.020 |
Why?
|
Expert Testimony | 1 | 2012 | 361 | 0.020 |
Why?
|
Acute Kidney Injury | 2 | 2012 | 1926 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2008 | 6234 | 0.020 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2011 | 284 | 0.020 |
Why?
|
Hospitals, Community | 1 | 2011 | 367 | 0.020 |
Why?
|
Databases, Factual | 2 | 2015 | 7980 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2007 | 7403 | 0.020 |
Why?
|
Quality of Health Care | 2 | 2015 | 4317 | 0.020 |
Why?
|
Postoperative Period | 1 | 2013 | 1812 | 0.020 |
Why?
|
Hospital Costs | 1 | 2014 | 960 | 0.020 |
Why?
|
Ultrasonography | 2 | 2012 | 5952 | 0.020 |
Why?
|
Health Status | 2 | 2017 | 4071 | 0.020 |
Why?
|
Propensity Score | 1 | 2015 | 1907 | 0.020 |
Why?
|
Life Expectancy | 1 | 2014 | 1244 | 0.020 |
Why?
|
Drug Combinations | 1 | 2013 | 2020 | 0.020 |
Why?
|
Emergency Service, Hospital | 2 | 2011 | 7810 | 0.020 |
Why?
|
Pyrroles | 1 | 2013 | 1130 | 0.020 |
Why?
|
Thrombolytic Therapy | 1 | 1996 | 2060 | 0.020 |
Why?
|
Ischemic Attack, Transient | 1 | 2012 | 878 | 0.020 |
Why?
|
Comprehension | 1 | 2012 | 619 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2017 | 2751 | 0.020 |
Why?
|
Hemoglobins | 1 | 2013 | 1519 | 0.020 |
Why?
|
Iatrogenic Disease | 1 | 2010 | 538 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2018 | 1831 | 0.020 |
Why?
|
Antibodies, Monoclonal | 2 | 2015 | 9160 | 0.020 |
Why?
|
Pilot Projects | 3 | 2012 | 8553 | 0.020 |
Why?
|
Anticholesteremic Agents | 1 | 2013 | 963 | 0.020 |
Why?
|
Drug Costs | 1 | 2014 | 1178 | 0.020 |
Why?
|
Hyperplasia | 1 | 2009 | 1154 | 0.020 |
Why?
|
Blood Transfusion | 1 | 2013 | 1321 | 0.020 |
Why?
|
Creatinine | 1 | 2011 | 1892 | 0.020 |
Why?
|
Activities of Daily Living | 2 | 2008 | 2414 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2017 | 22029 | 0.020 |
Why?
|
Platelet Count | 1 | 2008 | 775 | 0.020 |
Why?
|
Tunica Intima | 1 | 2007 | 459 | 0.020 |
Why?
|
Algorithms | 2 | 2009 | 13961 | 0.010 |
Why?
|
Smoking Cessation | 1 | 2016 | 2055 | 0.010 |
Why?
|
Eligibility Determination | 1 | 2008 | 419 | 0.010 |
Why?
|
Information Dissemination | 1 | 2012 | 1129 | 0.010 |
Why?
|
Health Planning Guidelines | 1 | 2004 | 151 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2014 | 2768 | 0.010 |
Why?
|
Angina, Unstable | 1 | 2007 | 887 | 0.010 |
Why?
|
Belgium | 1 | 2002 | 118 | 0.010 |
Why?
|
Quebec | 1 | 2002 | 140 | 0.010 |
Why?
|
Arrhythmias, Cardiac | 1 | 2012 | 2248 | 0.010 |
Why?
|
Medical Staff, Hospital | 1 | 2006 | 600 | 0.010 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2008 | 1240 | 0.010 |
Why?
|
Drug Utilization | 1 | 2008 | 1187 | 0.010 |
Why?
|
Infusions, Intra-Arterial | 1 | 2001 | 221 | 0.010 |
Why?
|
Patient Care Team | 1 | 2012 | 2504 | 0.010 |
Why?
|
Hemorheology | 1 | 2001 | 144 | 0.010 |
Why?
|
Tomography, Optical Coherence | 1 | 2014 | 2877 | 0.010 |
Why?
|
Heart Rate | 1 | 2012 | 4166 | 0.010 |
Why?
|
Emergency Medical Services | 1 | 2012 | 1915 | 0.010 |
Why?
|
Neural Conduction | 1 | 1981 | 441 | 0.010 |
Why?
|
Cineangiography | 1 | 1999 | 112 | 0.010 |
Why?
|
Cost of Illness | 1 | 2009 | 1936 | 0.010 |
Why?
|
Probability | 1 | 2005 | 2467 | 0.010 |
Why?
|
Punctures | 1 | 2000 | 365 | 0.010 |
Why?
|
Vitamin B 12 | 1 | 1981 | 522 | 0.010 |
Why?
|
Survivors | 1 | 2009 | 2370 | 0.010 |
Why?
|
Patient Admission | 1 | 2004 | 1372 | 0.010 |
Why?
|
Demography | 1 | 2002 | 1651 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2009 | 3671 | 0.010 |
Why?
|
Factor XII Deficiency | 1 | 1996 | 3 | 0.010 |
Why?
|
Motor Neurons | 1 | 1981 | 864 | 0.010 |
Why?
|
Antibodies, Antiphospholipid | 1 | 1996 | 71 | 0.010 |
Why?
|
Syndrome | 1 | 2002 | 3262 | 0.010 |
Why?
|
Mental Health | 2 | 2000 | 3234 | 0.010 |
Why?
|
Radiographic Image Enhancement | 1 | 1999 | 875 | 0.010 |
Why?
|
Emergencies | 1 | 2001 | 1209 | 0.010 |
Why?
|
Educational Status | 1 | 2000 | 2513 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20500 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2000 | 2690 | 0.010 |
Why?
|
Chronic Disease | 1 | 2004 | 9267 | 0.010 |
Why?
|
Forecasting | 1 | 1998 | 2923 | 0.000 |
Why?
|
Neoplasms | 1 | 2015 | 22032 | 0.000 |
Why?
|
Adolescent | 1 | 2011 | 87892 | 0.000 |
Why?
|
Animals | 1 | 2011 | 167768 | 0.000 |
Why?
|